CYP2D6 is the only gene that has pharmacogenomic prescribing guidance for any opioid; however, this is currently limited to the weak opioids codeine and tramadol [11], limiting its application in cancer pain prescribing where more potent opioids are usually required [2,9,12,13]. The gene discussed is CYP2D6; the disease is cancer.